Study of ZIO-101 in Multiple Myeloma

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Phase 1/Phase 2

Ziopharm